Avanzanite Bioscience reports on the Zulassung by the European Commission of Arzneimittels for seltene Leiden AKANTIOR Seite 1

Avanzanite Bioscience BV, a specialized pharmaceutical company, has developed a new drug on the market, that is to say that the European Commission (EC) has established the market for AKANTIOR (Polihexanid) for the treatment of Acanthamöben-Keratitis (AK) in adults and children aged 12 years and over. The form that the European Commission has adopted has made the positive notification of the positive attitude of the Australian Medicines Agency (CHMP) of the European Medicines Agency (EMA) who has conducted a positive study of the EMA approvals for the Medicines for Seltene Leiden (COMP). After more than 16 years of Research and Development (F&E), AKANTIOR is the first and only approved Medicines for the treatment of AK-weltweit.

This press conference resulted in a multimedia inhalation. The complete Mitteilung can be found here: https://www.businesswire.com/news/home/20240826278963/de/